Dare Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DARE research report →
About the company
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
- CEO
- Sabrina Martucci Johnson
- IPO
- 2014
- Employees
- 23
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $19.90M
- P/E
- -2.01
- P/S
- 17.20
- P/B
- 41.33
- EV/EBITDA
- -0.31
- Div Yield
- 0.00%
- Gross Margin
- 5.57%
- Op Margin
- -1034.38%
- Net Margin
- -1038.77%
- ROE
- 763.44%
- ROIC
- -151.41%
- Revenue
- $1.03M · 10429.36%
- Net Income
- $-13,399,274 · -230.55%
- EPS
- $-1.20 · -150.00%
- Op Income
- $-13,552,334
- FCF YoY
- -313.04%
- 52W High
- $9.19
- 52W Low
- $1.27
- 50D MA
- $2.28
- 200D MA
- $1.99
- Beta
- 1.02
- Avg Volume
- 634.41K
Get TickerSpark's AI analysis on DARE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Grossman Jessica D. | other | 26,066 |
| Jun 30, 26 | Kelley Susan L. | other | 23,696 |
| Jun 30, 26 | Matz Gregory W | other | 30,805 |
| Jun 30, 26 | RASTETTER WILLIAM H | other | 38,862 |
| Jun 30, 26 | Steele Robin Joan | other | 26,540 |
| Jun 11, 26 | RASTETTER WILLIAM H | other | 10,000 |
| Jun 11, 26 | Kelley Susan L. | other | 10,000 |
| Jun 11, 26 | Steele Robin Joan | other | 10,000 |
| Jun 11, 26 | Matz Gregory W | other | 10,000 |
| Jun 11, 26 | Grossman Jessica D. | other | 10,000 |
Our DARE coverage
Recent articles, reports, and earnings notes.
No research on DARE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DARE report →Similar companies
Peers in the same neighborhood.